The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksS & U Regulatory News (SUS)

Share Price Information for S & U (SUS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,910.00
Bid: 1,890.00
Ask: 1,910.00
Change: 20.00 (1.06%)
Spread: 20.00 (1.058%)
Open: 1,910.00
High: 1,910.00
Low: 1,890.00
Prev. Close: 1,890.00
SUS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: S&U (SUS): Seeing recovery and adapting to grow

4 Apr 2022 07:00

Edison Investment Research Limited Edison Investment Research Limited: S&U (SUS): Seeing recovery and adapting to grow 04-Apr-2022 / 07:00 GMT/BST


 

London, UK, 4 April 2022

 

S&U (SUS): Seeing recovery and adapting to grow

S&U recorded a dramatic increase in profit in FY22, but the more telling point is that average pre-tax profit for FY22 and FY21 was nearly £33m, only slightly below the pre-pandemic level of £35m (FY20). In the meantime, the group has continued to refine and develop both its businesses, which should underpin medium-term growth even if the near-term macro background is uncertain.

Our estimates are increased slightly, with EPS raised by 2% and 3% for FY23 and FY24 respectively. Following the exceptionally low level of loan loss provisions in FY22 we expect a normalisation in FY23, hence the reduction in pre-tax profit between the two years, from £47m to £39m. This still leaves the prospective multiple only just above 9x. The disparity between profits and earnings growth in FY24 is the result of allowing for the increase in corporation tax to 25%. The historical and prospective yield of over 5% should be supportive for the share price.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Andrew Mitchell +44 (0)20 3681 2500 financials@edisongroup.com

Martyn King ++44 (0)20 3077 5745 financials@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1318165 04-Apr-2022 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
9th Apr 20247:00 amRNSPreliminary Unaudited FY Results to 31 Jan 24
25th Mar 20247:00 amRNSResults Presentations for Analysts and Investors
9th Feb 20247:00 amRNSTrading Statement and Notice of Results
1st Feb 20242:30 pmRNSNotice of Trading Update
11th Jan 20242:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSTrading Statement to 11 December 2023
31st Oct 20232:29 pmRNSDirector/PDMR and PCA Shareholding
5th Oct 20237:00 amRNSDirectorate Change
3rd Oct 20237:00 amRNSInterim Results for the 6 months to 31 July 2023
4th Sep 20237:00 amRNSNotice of Results and Investor Presentation
10th Aug 20237:00 amRNSTrading Update and Notice of Results
25th Jul 202311:34 amRNSDirector/PDMR Shareholding
17th Jul 20233:34 pmRNSDirector/PDMR Shareholding
26th May 20234:38 pmRNSDirector/PDMR Shareholding
25th May 202312:43 pmRNSResult of AGM
25th May 20237:00 amRNSAGM Statement and Trading Update
25th Apr 20232:00 pmRNSAnnual Report and Accounts
25th Apr 202311:48 amRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSMello Investor Presentation
6th Apr 20234:08 pmRNSAnnouncement of Annual Report and Accounts
28th Mar 20234:35 pmRNSPrice Monitoring Extension
28th Mar 20237:00 amRNSPreliminary Results
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSResults Presentations for Analysts and Investors
14th Feb 20232:00 pmRNSAppointment of Executive Director
9th Feb 20237:00 amRNSTrading Statement and Notice of Results
8th Dec 20227:00 amRNSTrading Statement
27th Sep 20227:00 amRNSInterim Results
30th Aug 20227:00 amRNSResults Presentations for Analysts and Investors
18th Aug 20224:36 pmRNSPrice Monitoring Extension
10th Aug 20227:00 amRNSTrading Update and Notice of Results
3rd Aug 20224:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
8th Jul 20225:06 pmRNSDirector/PDMR and PCA Shareholding
1st Jun 20227:00 amRNSTotal Voting Rights
26th May 202212:33 pmRNSResult of AGM
26th May 20227:00 amRNSAGM Statement and Trading Update
23rd May 20227:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
18th May 202211:30 amRNSOptions, Director/PDMR Shareholding, Voting Rights
13th May 20224:33 pmRNSDirector/PDMR Shareholding
5th May 20221:53 pmRNSDirector/PDMR Shareholding, Options, Voting Rights
26th Apr 20222:00 pmRNSAnnual Report and Accounts
4th Apr 20227:00 amEQSEdison Investment Research Limited: S&U (SUS): Seeing recovery and adapting to grow
4th Apr 20227:00 amRNSAnnual Report and Accounts
29th Mar 20227:00 amRNSPreliminary Results
9th Mar 20227:00 amRNSResults Presentations for Analysts and Investors
10th Feb 20227:00 amRNSTrading Statement and Notice of Results
17th Jan 20222:39 pmRNSAppointment of non-executive director
17th Jan 20222:33 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.